Nasdaq-listed BioNTech, which is testing a COVID-19 vaccine candidate, said Monday it raised $250 million from Singapore state-owned investment company Temasek Holdings and other accredited investors in a private placement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
